Vir Biotechnology Hepatitis Delta Treatment Meets Phase III Goals, With 79% Virus-Free at Week 48
Morgan Stanley Maintains Overweight on Vir Biotechnology, Raises Price Target to $28
Evercore ISI Group Maintains Outperform on Vir Biotechnology, Raises Price Target to $25
Wall Street Analysts Predict a 75.59% Upside in Vir Biotechnology (VIR): Here's What You Should Know
Loading...